

## Press release

Contact: Torben Jörgensen, President and CEO Tel: +46 707 49 05 84, <u>torben.jorgensen@biotage.com</u>

Uppsala 16 October, 2012

## **Biotage AB Nomination Committee**

A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2013, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto.

The members of the Nomination Committee are:

Staffan Josephson, Investor Growth Capital, chairman

Anders Walldov, Brohuvudet AB and direct holding

Jesper Bonnevier, Länsförsäkringar Fonder

Ove Mattsson, Chairman of the Board, holding by endowment insurances

Shareholders wishing to submit a proposal for members of the Board of Directors may do so by sending e-mail to the Chairman of the Board of Directors of Biotage AB at: <u>info@biotage.com</u>

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.00 on 16 October 2012.

About Biotage

Biotage AB Box 8 SE-751 03 Uppsala Tel+46 18 56 59 00 www.biotage.com

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has 270 employees and had sales of 428.4 MSEK in 2011. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com